X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs GLENMARK PHARMA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD GLENMARK PHARMA LUPIN LTD/
GLENMARK PHARMA
 
P/E (TTM) x 23.0 14.4 160.0% View Chart
P/BV x 3.1 3.8 82.1% View Chart
Dividend Yield % 0.8 0.3 253.0%  

Financials

 LUPIN LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    LUPIN LTD
Mar-17
GLENMARK PHARMA
Mar-17
LUPIN LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,750993 176.2%   
Low Rs1,384729 189.7%   
Sales per share (Unadj.) Rs387.4325.5 119.0%  
Earnings per share (Unadj.) Rs56.639.3 144.1%  
Cash flow per share (Unadj.) Rs76.848.7 157.9%  
Dividends per share (Unadj.) Rs7.502.00 375.0%  
Dividend yield (eoy) %0.50.2 206.1%  
Book value per share (Unadj.) Rs298.9159.2 187.7%  
Shares outstanding (eoy) m451.58282.17 160.0%   
Bonus/Rights/Conversions ESOPSESOP-  
Price / Sales ratio x4.02.6 152.9%   
Avg P/E ratio x27.721.9 126.2%  
P/CF ratio (eoy) x20.417.7 115.2%  
Price / Book Value ratio x5.25.4 96.9%  
Dividend payout %13.25.1 260.2%   
Avg Mkt Cap Rs m707,513242,991 291.2%   
No. of employees `00016.813.0 129.5%   
Total wages/salary Rs m28,49516,408 173.7%   
Avg. sales/employee Rs Th10,418.37,083.9 147.1%   
Avg. wages/employee Rs Th1,697.01,265.4 134.1%   
Avg. net profit/employee Rs Th1,523.0855.1 178.1%   
INCOME DATA
Net Sales Rs m174,94391,857 190.5%  
Other income Rs m1,065374 285.1%   
Total revenues Rs m176,00892,230 190.8%   
Gross profit Rs m44,93120,367 220.6%  
Depreciation Rs m9,1222,644 345.1%   
Interest Rs m1,5252,373 64.3%   
Profit before tax Rs m35,34915,724 224.8%   
Minority Interest Rs m-720-   
Prior Period Items Rs m830-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m9,7853,827 255.7%   
Profit after tax Rs m25,57511,088 230.7%  
Gross profit margin %25.722.2 115.8%  
Effective tax rate %27.724.3 113.7%   
Net profit margin %14.612.1 121.1%  
BALANCE SHEET DATA
Current assets Rs m119,54268,746 173.9%   
Current liabilities Rs m61,20627,027 226.5%   
Net working cap to sales %33.345.4 73.4%  
Current ratio x2.02.5 76.8%  
Inventory Days Days7685 89.4%  
Debtors Days Days9096 94.1%  
Net fixed assets Rs m131,66024,132 545.6%   
Share capital Rs m903282 320.1%   
"Free" reserves Rs m134,07344,643 300.3%   
Net worth Rs m134,97644,925 300.4%   
Long term debt Rs m56,47845,363 124.5%   
Total assets Rs m266,073117,639 226.2%  
Interest coverage x24.27.6 317.0%   
Debt to equity ratio x0.41.0 41.4%  
Sales to assets ratio x0.70.8 84.2%   
Return on assets %10.211.4 89.0%  
Return on equity %18.924.7 76.8%  
Return on capital %19.319.1 100.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m81,88556,152 145.8%   
Fx outflow Rs m21,5068,084 266.0%   
Net fx Rs m60,37848,068 125.6%   
CASH FLOW
From Operations Rs m41,1486,574 625.9%  
From Investments Rs m-25,287-7,124 355.0%  
From Financial Activity Rs m4,3325,432 79.8%  
Net Cashflow Rs m20,1931,992 1,013.5%  

Share Holding

Indian Promoters % 46.6 48.3 96.5%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 6.9 163.8%  
FIIs % 31.9 34.4 92.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 10.5 96.2%  
Shareholders   98,259 56,727 173.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   ORCHID PHARMA LTD  CIPLA  ABBOTT INDIA  ALEMBIC LTD  WYETH LTD  

Compare LUPIN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 300 Points; Tata Steel Up 3.5%(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading near all-time high levels. Sectoral indices are trading on a positive note.

Related Views on News

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Jan 23, 2018 03:33 PM

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - ASTRAZENECA PHARMA COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS